H.C. Wainwright Asserts Buy Stance on Gossamer Bio Inc. (GOSS) on Pulmonary Arterial Hypertension Drug Prospects

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best Robinhood penny stocks to invest in. The stock has shown strong momentum, rallying by more than 100% year to date. Likewise, on August 19, analysts at H.C. Wainwright reiterated a ‘Buy’ rating on the stock with a $10 price target.

Copyright: dolgachov / 123RF Stock Photo

The research firm’s positive stance is based on the anticipation of key clinical data expected early next year. It has already conducted a literature review of seralutinib, the company’s investigational drug for pulmonary arterial hypertension, and affirmed its positive outlook.

Data review from a Phase 2 TORREY trial underscored sustained hemodynamic and functional improvements through 72 weeks of treatment. Additionally, the trial demonstrated a continued reduction in pulmonary vascular resistance and an improvement in six-minute walk distance among patients. The research firm is optimistic that Gossamer will deliver a positive Phase 3 PROSERA trial, which will affirm the drug’s potential as a disease-modifying therapy.

Gossamer Bio Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for rare diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

READ NEXT: 12 Best Cybersecurity Stocks to Buy Right Now and 10 Best American Mining Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.